Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 2606.

https://doi.org/10.1182/blood-2021-146987

Published: 2021

Journal Articles

Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 2824.

https://doi.org/10.1182/blood.V128.22.2824.2824

Published: 2016

Journal Articles

Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody® Antibody Treatment

Alexander Babich, Yingzhe Li, Francois Gaudet, Fei Huang, Kate Sasser, Mark Salvati, Anna Kalota

Blood (2016) 128 (22): 5215.

https://doi.org/10.1182/blood.V128.22.5215.5215

Published: 2016

Journal Articles

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells

Rachel C. Lynn, Mathilde Poussin, Anna Kalota, Yang Feng, Philip S. Low, Dimiter S. Dimitrov, Daniel J. Powell, Jr

Blood (2015) 125 (22): 3466–3476.

https://doi.org/10.1182/blood-2014-11-612721

Published: 2015

Includes: Supplemental data

Journal Articles

Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis

Anna Kalota, PhD, Grace R Jeschke, Martin Carroll, MD, Elizabeth Hexner

Blood (2011) 118 (21): 2825.

https://doi.org/10.1182/blood.V118.21.2825.2825

Published: 2011

Journal Articles

A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells

Anna Kalota, Alan M. Gewirtz

Blood (2010) 115 (1): 89–93.

https://doi.org/10.1182/blood-2009-06-227751

Published: 2010

Includes: Supplemental data

Journal Articles

C-Myb Associates with MLL1 through Menin, Augments MLL1's H3K4 Methylation Activity, and Regulates Hoxa9 and Meis1 Gene Expression in Primary Human Leukemia Cells.

Shenghao Jin, PhD, Huiwu Zhao, PhD, Yan Yi, PhD, Yuji Nakata, MD, Anna Kalota, PhD, Alan M. Gewirtz, MD

Blood (2009) 114 (22): 448.

https://doi.org/10.1182/blood.V114.22.448.448

Published: 2009

Journal Articles

The c- myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells

Huiwu Zhao, Anna Kalota, Shenghao Jin, Alan M. Gewirtz

Blood (2009) 113 (3): 505–516.

https://doi.org/10.1182/blood-2008-01-136218

Published: 2009

Journal Articles

Trisomy 21 enhances human fetal erythro-megakaryocytic development

Stella T. Chou, Joanna B. Opalinska, Yu Yao, Myriam A. Fernandes, Anna Kalota, John S. J. Brooks, John K. Choi, Alan M. Gewirtz, Gwenn-ael Danet-Desnoyers, Richard L. Nemiroff, Mitchell J. Weiss

Blood (2008) 112 (12): 4503–4506.

https://doi.org/10.1182/blood-2008-05-157859

Published: 2008

Includes: Supplemental data

Journal Articles

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Noelle V Frey, Anna Kalota, Melissa Potuzak, Doris Shank, Cezary R Swider, Alison Loren, Edward Stadtmauer, Alexander Perl, Adam Cuker, Barbara Konkle, Suman Sood, Steven Goldstein, Margaret Kasner, David L Porter, Selina M Luger, Alan M Gewirtz

Blood (2008) 112 (11): 4033.

https://doi.org/10.1182/blood.V112.11.4033.4033

Published: 2008

Journal Articles

A Nonpeptidyl, Hydrazone Class, Thrombopoietin Receptor Agonist (TpoRA), SB559457, Selectively Kills Primary Human Myeloid Leukemia Cells

Anna Kalota, PhD, Alan M. Gewirtz, MD

Blood (2008) 112 (11): 2636.

https://doi.org/10.1182/blood.V112.11.2636.2636

Published: 2008

Journal Articles

The c-myb Protooncogene and microRNA (miR)-15a Form an Autoregulatory Loop That May Play a Role in Normal Human Erythropoiesis.

Huiwu Zhao, PhD, Anna Kalota, Ph.D., Shenghao Jin, Ph.D., Alan Gewirtz, M.D.

Blood (2007) 110 (11): 2642.

https://doi.org/10.1182/blood.V110.11.2642.2642

Published: 2007

Journal Articles

A New Subtype of T-Cell Acute Leukemia in Very Young Children Is Defined by a Translocation Targeting the C-MYB Oncogene, and a Specific Gene Expression Signature.

Emmanuelle Clappier, Wendy Cuccuini, Anna Kalota, Antoine Crinquette, Jean-Michel Cayuela, PhD, Willem A. Dik, PhD, Anton W. Langerak, PhD, Bertrand Montpellier, Bertrand Nadel, PhD, Pierre Walrafen, PhD, Alain Aurias, MD, Thierry Leblanc, MD, Herve Dombret, MD, Alan M. Gewirtz, MD, Andre Baruchel, MD, Francois Sigaux, MD, Jean Soulier, MD, PhD

Blood (2007) 110 (11): 982.

https://doi.org/10.1182/blood.V110.11.982.982

Published: 2007

Journal Articles

The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children

Emmanuelle Clappier, Wendy Cuccuini, Anna Kalota, Antoine Crinquette, Jean-Michel Cayuela, Willem A. Dik, Anton W. Langerak, Bertrand Montpellier, Bertrand Nadel, Pierre Walrafen, Olivier Delattre, Alain Aurias, Thierry Leblanc, Hervé Dombret, Alan M. Gewirtz, André Baruchel, François Sigaux, Jean Soulier

Blood (2007) 110 (4): 1251–1261.

https://doi.org/10.1182/blood-2006-12-064683

Published: 2007

Includes: Supplemental data

Journal Articles

Myb Family Transcription Factors Contribute to G2/M Cell Cycle Transition in Normal and Malignant Hematopoietic Cells by Direct Regulation of Cyclin B1 Expression.

Yuji Nakata, MD, Susan Shetzline, PHD, Chizuko Sakashita, MD, Anna Kalota, MA, Stephen I. Rudnick, PhD, Alan M. Gewirtz, MD

Blood (2006) 108 (11): 1115.

https://doi.org/10.1182/blood.V108.11.1115.1115

Published: 2006

Journal Articles

Computationally Designed, Small Molecule Inhibitors of Tubulin Inhibit the Growth of Gleevec Resistant Chronic Myelogenous Leukemia Cells.

Anna Kalota, MS, Alan M. Gewirtz, MD

Blood (2006) 108 (11): 2173.

https://doi.org/10.1182/blood.V108.11.2173.2173

Published: 2006

Journal Articles

c-Myb Plays a Role InG2/M Cell Cycle Transition by Direct Regulation of Cyclin B1 Expression in Hematopoietic Cells.

Yuji Nakata, MD, Susan Shetzline, PhD, Chizuko Sakashita, MD, Anna Kalota, MA, Andrzej Ptasznik, MD, Yi Zhang, MD, Stephen G. Emerson, MD, PhD, Alan M. Gewirtz, MD

Blood (2005) 106 (11): 1355.

https://doi.org/10.1182/blood.V106.11.1355.1355

Published: 2005

Journal Articles

A Novel 2′-Deoxy-2′-Fluoro (2′F-ANA) Ribose Modification Significantly Enhances the Duration, and Efficiency, of Nucleic Acid Mediated Gene Silencing.

Anna Kalota, MS, Lidia Karabon, PhD, Cezary S. Swider, PhD, Ekaterina Viazovkina, PhD, Mohamed Elzagheid, PhD, Masad J. Damha, PhD, Alan M. Gewirtz, MD

Blood (2005) 106 (11): 3062.

https://doi.org/10.1182/blood.V106.11.3062.3062

Published: 2005

Journal Articles

Effects of SB559457, a Novel Small Molecule Thrombopoietin Receptor (TpoR) Agonist, on Human Hematopoietic Cell Growth and Differentiation.

Anna Kalota, MS, Kistin Brennan, Connie L. Erickson-Miller, Gwenn Danet, PhD, Martin Carroll, M.D., Alan M. Gewirtz, M.D.

Blood (2004) 104 (11): 2913.

https://doi.org/10.1182/blood.V104.11.2913.2913

Published: 2004

Journal Articles

Targeting Lyn Kinase with Short Interfering RNA (siRNA)-A Novel Therapeutic Strategy for Drug Resistant Chronic Myelogenous Leukemia (CML).

Andrzej Ptasznik, MD, PhD., Yuji Nakata, MD, Anna Kalota, Stephen G. Emerson, MD, PhD., Alan M. Gewirtz, MD

Blood (2004) 104 (11): 554.

https://doi.org/10.1182/blood.V104.11.554.554

Published: 2004

NARROW

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML)

Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody® Antibody Treatment

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells

Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis

A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells

C-Myb Associates with MLL1 through Menin, Augments MLL1's H3K4 Methylation Activity, and Regulates Hoxa9 and Meis1 Gene Expression in Primary Human Leukemia Cells.

The c- myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells

Trisomy 21 enhances human fetal erythro-megakaryocytic development

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

A Nonpeptidyl, Hydrazone Class, Thrombopoietin Receptor Agonist (TpoRA), SB559457, Selectively Kills Primary Human Myeloid Leukemia Cells

The c-myb Protooncogene and microRNA (miR)-15a Form an Autoregulatory Loop That May Play a Role in Normal Human Erythropoiesis.

A New Subtype of T-Cell Acute Leukemia in Very Young Children Is Defined by a Translocation Targeting the C-MYB Oncogene, and a Specific Gene Expression Signature.

The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children

Myb Family Transcription Factors Contribute to G2/M Cell Cycle Transition in Normal and Malignant Hematopoietic Cells by Direct Regulation of Cyclin B1 Expression.

Computationally Designed, Small Molecule Inhibitors of Tubulin Inhibit the Growth of Gleevec Resistant Chronic Myelogenous Leukemia Cells.

c-Myb Plays a Role InG2/M Cell Cycle Transition by Direct Regulation of Cyclin B1 Expression in Hematopoietic Cells.

A Novel 2′-Deoxy-2′-Fluoro (2′F-ANA) Ribose Modification Significantly Enhances the Duration, and Efficiency, of Nucleic Acid Mediated Gene Silencing.

Effects of SB559457, a Novel Small Molecule Thrombopoietin Receptor (TpoR) Agonist, on Human Hematopoietic Cell Growth and Differentiation.

Targeting Lyn Kinase with Short Interfering RNA (siRNA)-A Novel Therapeutic Strategy for Drug Resistant Chronic Myelogenous Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only